Exosens
1.12.2023 19:32:53 CET | ACCESS Newswire | Press release
Exosens signs a partnership with Scientific Imaging, Inc. to distribute its two main products brands: Photonis and Xenics.
MÉRIGNAC, FRANCE / ACCESSWIRE / December 1, 2023 / All products from Xenics and Photonis are covered in the distribution and partnership agreement with Scientific Imaging. The overall strategy of this partnership is to add commercial value to customers through a streamlined sales and service channel. This will provide access to a family of UV to NIR cameras (from Photonis) and SWIR and LWIR imaging systems (from Xenics) tailored to the US market. For Photonis and Xenics brands, this agreement is another step of broadening the market position by relying on Scientific Imaging's established user base of optics and imaging technologies and applications.
Scientific Imaging supplies best-in-class imaging solutions for a wide range of applications in Life Sciences, Microscopy, Inspection, Machine Vision and Quality Control. With a team of experienced professionals providing imaging solutions to meet the needs of imaging projects, Scientific Imaging is excited to bring its knowledge and expertise to help develop new sales opportunities with Photonis and Xenics products.
The wide range of high-performance cameras covered by the agreement also opens new horizons in various markets, with a greater purpose to improve and emphasize the specific needs of potential users in the region. For example, Xenics Manx series is the world's fastest InGaAs line-scan cameras with high-image resolutions. Xenics Wildcat+ series, with its high sensitivity and affordability, is the area-scan shortwave-infrared cameras with CameraLinkTM or plug-and-play USB3 Vision interfaces. In the long-wave infrared region, Xenics offers cameras and cores with low NETD options, a broader range of optics options and pixel resolutions for various thermal imaging needs. Photonis Nocturn series of low light imaging camera cores are ruggedized and passive with features like high-definition resolution, high sensitivity. iNocturn series from Photonis features a unique combination of ultra-sensitivity, low SWaP and high-frame-rate, high-QE photodetectors, and gating capability.
ABOUT EXOSENS:
Accompanied by Groupe HLD since 2021, EXOSENS is a high-tech company, with more than 85 years of experience in the innovation, development, manufacture and sale of technologies in the field of particles and photo detection and imaging. Today, it offers its customers detectors and detection solutions: its travelling wave tubes, advanced cameras, neutron & gamma detectors, instrument detectors and light intensifier tubes allow EXOSENS to respond to complex issues in environments extremely demanding by offering tailor-made solutions to its customers. Thanks to its sustained and permanent investment, EXOSENS is internationally recognized as a major innovator in optoelectronics, with production and R&D carried out on nine sites, in Europe and North America and over 1 500 employees.
For more information: exosens.com
Contact Information
Sales Manager
sales@xenics.com
SOURCE: Exosens
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/812404/exosens-signs-partnership-with-scientific-imaging-inc
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans30.9.2026 15:50:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally. Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match. The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata
Clean Air Metals Files Interim Financial Statements for the Six Months Ended July 31, 202630.9.2026 00:45:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / September 29, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the six-month period ended July 31, 2026, available for viewing on www.sedarplus.ca. Financial HighlightsTotal assets as at July 31, 2026 of $35,465,204Total cash as at July 31, 2026 of $422,500Working capital deficiency as at July 31, 2026 of $3,188,114Shareholder's equity as at July 31, 2026 of $31,803,864 During the six-month period ended July 31, 2026, the Company incurred $164,309 in cost for exploration activities at the Thunder Bay North project. During the second fiscal quarter, the Company focused on finalizing the proposed amalgamation while continuing discussions on Advanced Exploration permitting and re-assessment of past geophysical work to highlight areas of focus for drilling and geophysics in
Continent 8 and FuturePath AI Launch Future8: Accountable AI for Regulated Industries29.9.2026 15:00:00 CEST | Press release
LISBON, PT / ACCESS Newswire / September 29, 2026 / Continent 8 Technologies and FuturePath AI today launched Future8, an AI-native operating company built for regulated operators, formed as a joint venture between the two companies. Announced at SBC Summit Lisbon, Future8 combines FuturePath's enterprise AI applications platform with Continent 8's licensed global operating footprint, enabling the iGaming industry to deploy auditable AI without compromising compliance, data sovereignty and operational control. Built for highly regulated environments, Future8 enables operators to move from AI experimentation to production deployment by embedding governance, approvals and auditability into every workflow from day one. Continent 8 brings licensed data centers and a private global network spanning more than 100 locations, built over 28 years serving the biggest iGaming and online brands, along with AI-enabled Global Capability Centers in India, the Philippines and Bulgaria. The company als
Europe SPAC Summit 2026 Invites European Private Companies to Explore the SPAC Path to U.S. Public Markets29.9.2026 15:00:00 CEST | Press release
NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / A growing number of European companies in frontier technologies, critical minerals, advanced manufacturing, defense tech, energy, and consumer sectors are evaluating a merger with a special purpose acquisition company (SPAC) as a faster route to a U.S. listing, a valuation that reflects global investor demand, and access to follow-on capital. The Europe SPAC Summit 2026 (ESPAC'26), co-hosted by AUM Advisors and MBP Global, is inviting the CEOs, CFOs, founders, and board members of late-stage European private companies to The Dolder Grand in Zurich on Thursday, December 10, 2026, to learn how the process works and to meet the investment bankers, institutional investors, and SPAC sponsors who make these transactions happen. Attendance is by invitation only and free of charge for qualified companies. Europe's recent de-SPACs show what is possible. Kyivstar, Ukraine's largest mobile operator, listed on Nasdaq thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom